|1.||Molitch, Mark E: 10 articles (05/2014 - 01/2002)|
|2.||Hilfiker-Kleiner, Denise: 8 articles (11/2015 - 12/2007)|
|3.||Krysiak, Robert: 6 articles (10/2015 - 01/2011)|
|4.||Wu, Zhe Bao: 6 articles (09/2014 - 01/2006)|
|5.||Sliwa, Karen: 6 articles (03/2014 - 01/2010)|
|6.||Ezrokhi, Michael: 5 articles (01/2015 - 01/2007)|
|7.||Cincotta, Anthony H: 5 articles (01/2015 - 07/2010)|
|8.||Gaziano, J Michael: 5 articles (01/2015 - 01/2007)|
|9.||Colao, Annamaria: 5 articles (01/2010 - 06/2002)|
|10.||Pijl, Hanno: 5 articles (04/2009 - 01/2002)|
05/01/2013 - "Bromocriptine is an effective treatment for most prolactinomas. "
07/01/1981 - "In a case of sESS consecutive to the treatment with bromocriptine (for 6 months) of an invasive prolactinoma, TRH i. v. released PRL into the CSF but not into the blood, and the serum/ CSF ratio of PRL was very low, until a new cure with bromocriptine (for 3 months) mormalised it. "
06/15/1987 - "The therapy with bromocriptine reveals good results particularly in prolactinomas."
08/01/2004 - "the favourable response obtained in this patient implies that bromocriptine monotherapy can be an effective first-line treatment for children with prolactinoma."
06/01/1995 - "It is concluded that bromocriptine LAR is an effective treatment in the majority of patients with macroprolactinomas; it is also partially effective in some patients with GH secreting macroadenomas."
11/01/2012 - "The combination of Compound Xuanju Capsule and bromocriptine is highly effective in the treatment of hyperprolactinemia-induced ED, and its effect is even better than that of bromocriptine alone."
01/01/2015 - "Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse."
09/01/2003 - "Oral bromocriptine for 2 weeks in postpartum patients with SLE may relieve the disease from hyperprolactinemia and hyperestrogenemia, and may be beneficial in protecting the patients from disease relapse and in reducing the usage of steroid and immunosuppressant."
01/01/1993 - "Six of 11 patients exhibiting bromocriptine resistance showed a significant reduction in the degree of hyperprolactinaemia but normoprolactinaemia was achieved in only 1. Galactorrhoea ceased in 2 of 6 patients, menstruation resumed in 6 of 11 patients presenting with amenorrhoea, and 2 patients conceived. "
02/01/1989 - "In 13 patients PRL levels were maintained within the normal range with daily administration of 2.5 mg, whereas in two patients, PRL levels remained higher than normal despite an increase in bromocriptine dose to 5 mg. These results suggest that short term use of vaginal bromocriptine is a safe and effective method of therapy for hyperprolactinemia."
|3.||Parkinson Disease (Parkinson's Disease)
01/01/1990 - "This multicentre double-blind study compared the efficacy of low and very low dose bromocriptine in 64 elderly subjects with newly diagnosed Parkinson's disease. "
01/01/1988 - "For many years, bromocriptine has proven to be a useful treatment for some of the disabling motor effects seen in Parkinson's disease. "
06/01/1985 - "Bromocriptine, in low doses, is effective in patients with mild to moderate Parkinson's disease, while bromocriptine in higher doses is needed in patients with advanced disease. "
01/01/1997 - "A 10-year nationwide multicenter prospective study on the long-term efficacy of bromocriptine for Parkinson's disease is reported. "
08/11/1986 - "These findings may, in part, explain the long-term clinical efficacy of bromocriptine in patients with Parkinson's disease."
11/01/1994 - "Case 1 was treated with bromocriptine, leading to marked decrease in serum PRL levels and reduction of tumor size. "
03/01/2003 - "The patient was treated with bromocriptine and has shown a rapid improvement in her visual field and a regression of the tumor, as evidenced by a repeat MRI. "
07/01/1997 - "The frequencies of bromocriptine-resistant tumors (30 vs.5%; P < 0.01) and invasive macroadenomas (52 vs.27%; P < 0.001) were significantly greater in men than those in women. "
12/01/1984 - "A single dose of 5 mg bromocriptine elicited a significant reduction in FSH levels from 137 to 64 mIU/ml. Long term treatment with 15 mg/day bromocriptine resulted in further reduction of FSH level, to 36.4 mIU/ml, without any change in tumor size. "
06/01/1996 - "Preoperative bromocriptine therapy proved effective in reducing tumor size and serum PRL levels, but had no effect on the MIB-1 positive rate. "
|5.||Pituitary Neoplasms (Pituitary Adenoma)
12/01/1986 - "Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas."
03/01/1982 - "Bromocriptine causes a clinically significant reduction in size of nonsecreting as well as secreting pituitary tumors with the same success rate as that of conventional treatments.U"
04/01/2002 - "Although medical treatment with bromocriptine is effective for patients with pituitary adenomas, little is known about the molecular mechanisms of gene regulation mediated by D2 receptors. "
02/01/1989 - "Although it is well known that bromocriptine (BC) is effective in the treatment of functioning pituitary adenoma, this agent sometimes causes severe gastrointestinal side effects. "
04/01/1981 - "2.5 mg per day of bromocriptine has been effective in 2 patients without a pituitary adenoma and ineffective in the other 4 patients with a pituitary adenoma. "
|1.||Levodopa (L Dopa)
|3.||Dopamine Agonists (Dopamine Agonist)
|2.||Drug Therapy (Chemotherapy)